目的 了解2019年蘇州九龍醫(yī)院信迪利單抗的使用合理性。方法 對蘇州九龍醫(yī)院2019年1月-2019年12月使用過信迪利單抗的24例患者，63次用藥情況進行回顧性分析，按原發(fā)腫瘤進行分類，參考說明書及相關文獻信息對患者治療情況進行統(tǒng)計分析，評價其使用合理性。結果 信迪利單抗主要用于肺惡性腫瘤和結直腸惡性腫瘤，構成比分別為25.0%、16.7%；63次治療中，7次為單藥使用信迪利單抗，56次為聯(lián)合用藥；用藥療程中有7例無故中斷信迪利單抗的繼續(xù)治療；2次用量為單次100 mg，2次用量為200 mg分2次使用（間隔3~5 d）。用藥不合理主要表現(xiàn)為超適應癥用藥（100.0%）、聯(lián)合用藥不合理（3.2%）、用藥療程不合理（29.2%）和用法用量不合理（6.3%）4個方面。結論 蘇州九龍醫(yī)院信迪利單抗的超說明書應用情況普遍存在，鑒于PD-1類藥物特殊的抗腫瘤機制，隨著更多的相關臨床研究加速開展，信迪利單抗將在腫瘤治療中發(fā)揮更大的作用。

Objective To investigate the rationality of sintilimab in Suzhou Kowloon Hospital in 2019. Methods The application of sintilimab for 24 patients (63 times) were retrospectively analyzed and evaluated in Suzhou Kowloon Hospital from January 2019 to December 2019. The reasonable use of sintilimab was evaluated according to the classification of primary tumors, drug instructions, and relevant literature information. Results Sindelizumab was mainly used in lung and colorectal malignancies, accounted for 25.0% and 16.7%. In 63 times of treatment, zimidazumab was used as a monotherapy with 7 times, while zimidazumab was used as drug combination with 56 times. In the course of treatment, 7 cases were interrupted without reason. There was twice with dosage of 100 mg in a single dose, while twice with dosage of 200 mg in twice dose (interval of 3-5 d). The irrational use of sintilimab was mainly manifested in the following four aspects:off-label use (100.0%), irrational combination use (3.2%), irrational medication course (29.2%), and unreasonable usage and dosage (6.3%). Conclusion The off-label use of sintilimab is common in Suzhou Kowloon Hospital. In view of the special anti-tumor mechanism of PD-1, with the development of more relevant clinical research, sintilimab will play a greater role in tumor treatment.

R969.3